triamcinolonacetonid "paranova" 40 mg/ml injektionsvæske, suspension
paranova danmark a/s - triamcinolonacetonid - injektionsvæske, suspension - 40 mg/ml
zovirax 80 mg/ml oral suspension
paranova danmark a/s - aciclovir - oral suspension - 80 mg/ml
depo-medrol 40 mg/ml injektionsvæske, suspension
nordic prime aps - methylprednisolonacetat - injektionsvæske, suspension - 40 mg/ml
diprofos depot 7 mg/ml injektionsvæske, suspension
nordic prime aps - betamethasondinatriumphosphat, betamethasondipropionat - injektionsvæske, suspension - 7 mg/ml
solu-cortef 100 mg pulver og solvens til injektionsvæske, opløsning
2care4 aps - hydrocortisonnatriumsuccinat - pulver og solvens til injektionsvæske, opløsning - 100 mg
solu-medrol lactosefri 40 mg pulver og solvens til injektionsv?ske, opl?sning
pfizer aps - methylprednisolonnatriumsuccinat - pulver og solvens til injektionsvæske, opløsning - 40 mg
triamcinolonacetonid "2care4" 40 mg/ml injektionsvæske, suspension
2care4 aps - triamcinolonacetonid - injektionsvæske, suspension - 40 mg/ml
triamcinolonacetonid "orifarm" 40 mg/ml injektionsvæske, suspension
orifarm a/s - triamcinolonacetonid - injektionsvæske, suspension - 40 mg/ml
bexsero
gsk vaccines s.r.l. - ydre membran vesikler fra neisseria meningitidis gruppe b (stamme nz 98/254), rekombinant neisseria meningitidis gruppe b fhbp fusion protein, rekombinant neisseria meningitidis gruppe b nada protein, rekombinant neisseria meningitidis gruppe b nhba fusion protein - meningitis, meningokok - meningokokvacciner - aktiv immunisering mod invasiv sygdom forårsaget af neisseria meningitidis serogruppe b-stammer.
flebogamma dif (previously flebogammadif)
instituto grifols s.a. - humant normalt immunglobulin - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - immune sera og immunoglobuliner, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.